CRMI Reports Sufficient Internal Controls After Governance Review
I'm PortAI, I can summarize articles.
China Regenerative Medicine International Limited (CRMI) has reported that its internal control review, prompted by past non-compliance with GEM Listing Rules, has been positively assessed by an independent consultant. The consultant confirmed that CRMI's remedial measures are adequate, ensuring reliable governance and internal control systems. The Board and consultant will continue to oversee these systems for ongoing compliance.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments